CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880724208
- Phone
- 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- 144 Insider Sale of Securities
- 8-K Event Other events
- 424B5 Offering Prospectus
- 8-K Event Regulation FD disclosure · Other events
- 4 Open-market sale Chief Scientific Officer sold 6,567 shares at $30.05 ($197,338)
- 4 Open-market sale Chief Development Officer sold 2,840 shares at $30.05 ($85,342)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale Chief Executive Officer sold 10,916 shares at an average $29.64 ($323,508)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale Chief Scientific Officer sold 8,500 shares at an average $30.02 ($255,130)
- 4 Planned sale Chief Operating Officer sold 5,000 shares at $30.10 ($150,487)
- 4 Planned sale Chief Executive Officer sold 10,916 shares at an average $25.20 ($275,047)
- 4 Planned sale Chief Scientific Officer sold 8,500 shares at an average $25.19 ($214,091)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Planned sale Chief Scientific Officer sold 8,500 shares at an average $25.79 ($219,196)
Page 6 of 13 · 253 filings